Halozyme Therapeutics Inc (HALO) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.

Total Revenue Chart for Halozyme Therapeutics Inc

Halozyme Therapeutics Inc (HALO) revenue for FY2025 was USD 1.4B, a 37.6% change from FY2024. Halozyme Therapeutics Inc's revenue grew from USD 24.7K in 2001 to USD 1.4B in 2025 (5657631.4% over 24 years). Earnings per share moved from USD -0.19 in 2011 to USD 1.44 in 2022. Revenue compound annual growth rate: 5-year CAGR of 39.2%, 10-year CAGR of 26.3%, 20-year CAGR of 59.2%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$12.45B
Implied Share Price
$109.72
Enterprise Value
$14.68B
Revenue (TTM)
$1.66B
EBITDA
$1.05B
Profit Margin
24.86%
Trailing P/E
31.71
Forward P/E
11.45
Price/Book (MRQ)
88.91
Price/Sales (TTM)
7.49
EV/EBITDA
11.80
EV/Revenue
8.82
Dividend Yield
—
Book Value
$1.26
Free Cash Flow (FY2025)
$644.59M
Free Cash Flow Yield
5.18%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.